Vaxcyte, Inc. — Director's Dealing 2023

Dec 18, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2023-12-14

Reporting Person: GUGGENHIME ANDREW (President and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-14	Common Stock	M	14000	$5.35	Acquired	93474	Direct
2023-12-14	Common Stock	S	14000	$60.22	Disposed	79474	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-14	Stock Option (right to buy)	$5.35	M	14000	Disposed	2030-05-11	Common Stock (14000)	Direct

Footnotes

F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023.

F2: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter.